沉默信息调节因子在高血压发病机制中的研究进展
Research progress of sirtuins in pathogenesis of hypertension
查看参考文献47篇
文摘
|
高血压是多种心血管疾病的主要危险因素。尽管许多研究都强调了高血压的多因素性,但是高血压的发病机制仍然有待探索。大量证据表明,表观遗传学在高血压发病中起着重要的作用,其中烟酰胺腺嘌呤二核苷酸(nicotimide adenosine dinucleotide,NAD~+)依赖性酶家族介导的血管动态平衡和心血管疾病的表观遗传过程引起了研究者的广泛关注。分子水平上,NADPH氧化酶信号的激活、内源性抗氧化剂的抑制、DNA的甲基化、组蛋白的修饰和一氧化氮合酶(nitric oxide synthase,NOS)异构体蛋白表达的改变等共同参与了高血压的发病。沉默信息调节因子(sirtuins/silent information regulators,SIRTs)作为NAD+依赖的脱乙酰酶,参与了高血压的形成与发展。本文将综述SIRTs家族不同成员在高血压发病中的作用。 |
其他语种文摘
|
The formation of hypertension is closely related to the activation of nicotinamide adenine dinucleotide phosphate(NADPH)oxidase signal.Sirtuins as a family of nicotinamide adenine dinucleotide(NAD+)dependent enzymes,not only act on cardiomyocytes directly,but also participate in the regulation of vascular endothelial homeostasis,vascular stiffnessand remodeling.In addition,Sirtuins also affect blood pressure by changing with cell and vascular aging,participating in water and salt regulation,glucose and lipid metabolism,and even affect target organs such as the heart,most of which are positive regulation,which helps to reduce cardiovascular damage,a few are negative regulation,which promotes cardiovascular damage.This article reviews the different roles of sirtuins family members in the pathogenesis of hypertension. |
来源
|
中国病理生理杂志
,2021,37(11):2100-2106 【核心库】
|
DOI
|
10.3969/j.issn.1000-4718.2021.11.026
|
关键词
|
沉默信息调节因子
;
高血压
;
发病机制
;
危险因素
;
靶器官损害
|
地址
|
1.
兰州大学第一临床医学院, 甘肃, 兰州, 730000
2.
兰州大学第一医院, 甘肃, 兰州, 730000
3.
兰州大学第一医院心内科, 甘肃省心血管疾病重点实验室, 甘肃, 兰州, 730000
|
语种
|
中文 |
文献类型
|
综述型 |
ISSN
|
1000-4718 |
学科
|
基础医学;内科学 |
基金
|
甘肃省高等学校创新能力提升项目
;
兰州大学第一医院2018年度院内基金资助项目
|
文献收藏号
|
CSCD:7103602
|
参考文献 共
47
共3页
|
1.
Liang M. Epigenomics of hypertension.
Semin Nephrol,2013,33(4):392-399
|
CSCD被引
3
次
|
|
|
|
2.
Guarner-Lans V. Early programming of adult systemic essential hypertension.
Int J Mol Sci,2020,21(4):1203-1231
|
CSCD被引
3
次
|
|
|
|
3.
Mautone N. Sirtuin modulators: where are we now? A review of patents from 2015 to 2019.
Expert Opin Ther Pat,2020,30(6):389-407
|
CSCD被引
3
次
|
|
|
|
4.
Kane A E. Sirtuins and NAD in the development and treatment of metabolic and cardiovascular diseases.
Circ Res,2018,123(7):868-885
|
CSCD被引
19
次
|
|
|
|
5.
Kruger-Genge A. Vascular endothelial cell biology:an update.
Int J Mol Sci,2019,20(18):4411-4433
|
CSCD被引
44
次
|
|
|
|
6.
Guo J. Endothelial SIRT6 is vital to prevent hypertension and associated cardiorenal injury through targeting Nkx3.2-GATA5 signaling.
Circ Res,2019,124(10):1448-1461
|
CSCD被引
11
次
|
|
|
|
7.
Silva G C. Endothelial dysfunction in DOCA-salt-hypertensive mice:role of neuronal nitric oxide synthase-derived hydrogen peroxide.
Clin Sci(Lond),2016,130(11):895-906
|
CSCD被引
3
次
|
|
|
|
8.
Mattagajasingh I. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase.
Proc Natl Acad Sci U S A,2007,104(37):14855-14860
|
CSCD被引
29
次
|
|
|
|
9.
Gano L B. The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production,and inflammation with aging in mice.
Am J Physiol Heart Circ Physiol,2014,307(12):1754-1763
|
CSCD被引
10
次
|
|
|
|
10.
Kumar S. Sirtuin1-regulated lysine acetylation of p66Shc governs diabetes-induced vascular oxidative stress and endothelial dysfunction.
Proc Natl Acad Sci U S A,2017,114(7):1714-1719
|
CSCD被引
10
次
|
|
|
|
11.
Dikalova A E. Mitochondrial deacetylase Sirt3 reduces vascular dysfunction and hypertension while Sirt3 depletion in essential hypertension is linked to vascular inflammation and oxidative stress.
Circ Res,2020,126(4):439-452
|
CSCD被引
18
次
|
|
|
|
12.
He X. Endothelial specific SIRT3 deletion impairs glycolysis and angiogenesis and causes diastolic dysfunction.
J Mol Cell Cardiol,2017,112(11):104-113
|
CSCD被引
7
次
|
|
|
|
13.
Jin Z. SIRT6 inhibits cholesterol crystal-induced vascular endothelial dysfunction via Nrf2 activation.
Exp Cell Res,2020,387(1):111744-111754
|
CSCD被引
1
次
|
|
|
|
14.
Sun Z. Aging,arterial stiffness,and hypertension.
Hypertension,2015,65(2):252-256
|
CSCD被引
11
次
|
|
|
|
15.
Gao D. Activation of SIRT1 attenuates Klotho deficiency-induced arterial stiffness and hypertension by enhancing AMP-activated protein kinase activity.
Hypertension,2016,68(5):1191-1199
|
CSCD被引
9
次
|
|
|
|
16.
Fry J L. Vascular smooth muscle sirtuin-1 protects against diet-induced aortic stiffness.
Hypertension,2016,68(3):775-784
|
CSCD被引
4
次
|
|
|
|
17.
Lu C L. Sirtuin-1 and its relevance in vascular calcification.
Int J Mol Sci,2020,21(5):1593-1612
|
CSCD被引
4
次
|
|
|
|
18.
Bai B. Cyclin-dependent kinase 5-mediated hyperphosphorylation of sirtuin-1 contributes to the development of endothelial senescence and atherosclerosis.
Circulation,2012,126(6):729-740
|
CSCD被引
4
次
|
|
|
|
19.
Bai B. Loss-of-SIRT1 function during vascular ageing:hyperphosphorylation mediated by cyclin-dependent kinase 5.
Trends Cardiovasc Med,2014,24(2):81-84
|
CSCD被引
3
次
|
|
|
|
20.
Law I K M. Identification and characterization of proteins interacting with SIRT1 and SIRT3: implications in the anti-aging and metabolic effects of sirtuins.
Proteomics,2009,9(9):2444-2456
|
CSCD被引
1
次
|
|
|
|
|